Last reviewed · How we verify
Continuous PD-1 inhibitor therapy
Continuous PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells, preventing tumor cells from suppressing anti-tumor immune responses.
Continuous PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells, preventing tumor cells from suppressing anti-tumor immune responses. Used for Cancer (specific tumor type under investigation in Canadian Cancer Trials Group phase 3 trial).
At a glance
| Generic name | Continuous PD-1 inhibitor therapy |
|---|---|
| Sponsor | Canadian Cancer Trials Group |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1 inhibitors work by binding to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells. This blockade restores T cell activation and proliferation, enabling the immune system to recognize and attack cancer cells. Continuous dosing aims to maintain sustained immune checkpoint inhibition compared to standard intermittent schedules.
Approved indications
- Cancer (specific tumor type under investigation in Canadian Cancer Trials Group phase 3 trial)
Common side effects
- Fatigue
- Immune-related colitis
- Pneumonitis
- Hepatotoxicity
- Rash
- Hypothyroidism
Key clinical trials
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Duration of Anti-PD-1 Therapy in Metastatic Melanoma (PHASE3)
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (PHASE1, PHASE2)
- Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) (PHASE3)
- Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (PHASE2)
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (PHASE3)
- Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous PD-1 inhibitor therapy CI brief — competitive landscape report
- Continuous PD-1 inhibitor therapy updates RSS · CI watch RSS
- Canadian Cancer Trials Group portfolio CI